Table 1.
Comparisons of virologic outcomes of study cohort.
| Demographic | Total (n = 150) | Virologic success (n = 116) | Virologic failure (n = 34) |
|---|---|---|---|
| Male sex; n (%) | 143 (95) | 110 (95) | 33 (97) |
| Age; mean years (range) | 42 (23–67) | 42 (23–67) | 40 (27–58) |
| Ethnicity; n (%) | 149 (100) | ||
| White | 106 (71) | 85 (74) | 21 (62) |
| African–American | 8 (5) | 5 (4) | 3 (9) |
| Latino/a | 24 (16) | 16 (14) | 8 (24) |
| Other | 11 (7) | 9 (8) | 2 (6) |
| HIV risk factor; n (%) | |||
| MSM | 136 (91) | 104 (90) | 32 (94) |
| MSM + IDU | 3 (2) | 3 (2) | 0 (0) |
| Heterosexual | 11 (7) | 9 (8) | 2 (6) |
| Viral load at start of ART; mean log10HIV RNA copies/ml (range) |
3.9 (1.1–6.4) N = 147 | 3.8 (1.1–6.4) N = 114 | 4.1 (2.6–5.8) N = 33 |
| CD4 cell count at start of ART; median cells/µl (range) |
466 (85–1332) N = 149 | 466 (85–1332) N = 115 | 470 (153–920) N = 34 |
| CD4 cell count after 6 months of ART; median cells/µl (range) |
583 (203–1301) | 610 (203–1301) | 511 (254–827) |
| Nonclade B; n (%) | 3 (2) | 3 (3) | 0 (0) |
| Baseline drug resistancea | |||
| Total missing; n (%) | 17 (11) | 11 (9) | 6 (18) |
| Any drug; n (%) | 17 (13) | 13 (12) | 4 (14) |
| NRTI; n (%) | 6 (5) | 5 (5) | 1 (4) |
| NNRTI; n (%) | 12 (9) | 9 (9) | 3 (11) |
| PI; n (%) | 5 (4) | 3 (3) | 2 (7) |
| ART regimen | |||
| PI based; n (%) | 71 (47) | 52 (45) | 19 (56) |
| NNRTI based; n (%) | 57 (38) | 48 (41) | 9 (26) |
| PI and NNRTI; n (%) | 11 (7) | 7 (6) | 2 (6) |
| NRTI only; n (%) | 11 (7) | 9 (8) | 2 (6) |
Virologic success defined as viral load less than 50 HIV RNA copies/ml after 6 months of ART. ART, antiretroviral treatment; IDU, injection drug users; MSM, men who have sex with men; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
a
Rates of HIV-1 clade and drug resistance were calculated on available genotypic data.